The Remnant Lipoprotein Hypothesis of Diabetes-Associated Cardiovascular Disease

被引:14
作者
Bornfeldt, Karin E. [1 ,2 ]
机构
[1] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA
[2] Univ Washington, Dept Lab Med & Pathol, Med Diabet Inst, Seattle, WA USA
基金
美国国家卫生研究院;
关键词
atherosclerosis; biomarkers; humans; hyperglycemia; lipoproteins; TRIGLYCERIDE-RICH LIPOPROTEINS; LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN C-III; CHOLESTEROL-FED RABBITS; ATHEROSCLEROTIC LESIONS; INSULIN-RESISTANCE; MACROPHAGE PHENOTYPE; ELEVATED GLUCOSE; GENE-EXPRESSION; LIPASE ACTIVITY;
D O I
10.1161/ATVBAHA.122.317163
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Both type 1 and type 2 diabetes are associated with an increased risk of atherosclerotic cardiovascular disease (CVD). Research based on human-first or bedside-to-bench approaches has provided new insights into likely mechanisms behind this increased risk. Although both forms of diabetes are associated with hyperglycemia, it is becoming increasingly clear that altered lipoprotein metabolism also plays a critical role in predicting CVD risk in people with diabetes. This review examines recent findings indicating that increased levels of circulating remnant lipoproteins could be a missing link between diabetes and CVD. Although CVD risk associated with diabetes is clearly multifactorial in nature, these findings suggest that we should increase efforts in evaluating whether remnant lipoproteins or the proteins that govern their metabolism are biomarkers of incident CVD in people living with diabetes and whether reducing remnant lipoproteins will prevent the increased CVD risk associated with diabetes.
引用
收藏
页码:819 / 830
页数:12
相关论文
共 116 条
  • [1] SGLT2 inhibition reduces atherosclerosis by enhancing lipoprotein clearance in Ldlr-/- type 1 diabetic mice
    Al-Sharea, Annas
    Murphy, Andrew J.
    Huggins, L. A.
    Hu, Y.
    Goldberg, Ira J.
    Nagareddy, Prabhakara R.
    [J]. ATHEROSCLEROSIS, 2018, 271 : 166 - 176
  • [2] N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels
    Alexander, Veronica J.
    Xia, Shuting
    Hurh, Eunju
    Hughes, Steven G.
    O'Dea, Louis
    Geary, Richard S.
    Witztum, Joseph L.
    Tsimikas, Sotirios
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 (33) : 2785 - 2796
  • [3] Empagliflozin in Heart Failure with a Preserved Ejection Fraction
    Anker, Stefan D.
    Butler, Javed
    Filippatos, Gerasimos
    Ferreira, Joao P.
    Bocchi, Edimar
    Boehm, Michael
    Brunner-La Rocca, Hans-Peter
    Choi, Dong-Ju
    Chopra, Vijay
    Chuquiure-Valenzuela, Eduardo
    Giannetti, Nadia
    Gomez-Mesa, Juan Esteban
    Janssens, Stefan
    Januzzi, James L.
    Gonzalez-Juanatey, Jose R.
    Merkely, Bela
    Nicholls, Stephen J.
    Perrone, Sergio V.
    Pina, Ileana L.
    Ponikowski, Piotr
    Senni, Michele
    Sim, David
    Spinar, Jindrich
    Squire, Iain
    Taddei, Stefano
    Tsutsui, Hiroyuki
    Verma, Subodh
    Vinereanu, Dragos
    Zhang, Jian
    Carson, Peter
    Lam, Carolyn Su Ping
    Marx, Nikolaus
    Zeller, Cordula
    Sattar, Naveed
    Jamal, Waheed
    Schnaidt, Sven
    Schnee, Janet M.
    Brueckmann, Martina
    Pocock, Stuart J.
    Zannad, Faiez
    Packer, Milton
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) : 1451 - 1461
  • [4] Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D
    Basu, Arpita
    Bebu, Ionut
    Jenkins, Alicia J.
    Stoner, Julie A.
    Mang, Ying
    Klein, Richard L.
    Lopes-Virella, Maria F.
    Garvey, W. Timothy
    Budoff, Matthew J.
    Alaupovic, Petar
    Lyons, Timothy J.
    [J]. JOURNAL OF LIPID RESEARCH, 2019, 60 (08) : 1432 - 1439
  • [5] Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanistic Studies in Animal Models
    Basu, Debapriya
    Bornfeldt, Karin E.
    [J]. FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [6] Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition
    Basu, Debapriya
    Huggins, Lesley-Ann
    Scerbo, Diego
    Obunike, Joseph
    Mullick, Adam E.
    Rothenberg, Paul L.
    Di Prospero, Nicholas A.
    Eckel, Robert H.
    Goldberg, Ira J.
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38 (09) : 2207 - 2216
  • [7] Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis
    Baumgartl, J
    Baudler, S
    Scherner, M
    Babaev, V
    Makowski, L
    Suttles, J
    McDuffie, M
    Fazio, S
    Kahn, CR
    Hotamisligil, GS
    Krone, W
    Linton, M
    Brüning, JC
    [J]. CELL METABOLISM, 2006, 3 (04) : 247 - 256
  • [8] Mediation of the Effect of Glycemia on the Risk of CVD Outcomes in Type 1 Diabetes: The DCCT/EDIC Study
    Bebu, Ionut
    Braffett, Barbara H.
    Orchard, Trevor J.
    Lorenzi, Gayle M.
    Lachin, John M.
    [J]. DIABETES CARE, 2019, 42 (07) : 1284 - 1289
  • [9] Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis
    Biddinger, Sudha B.
    Hernandez-Ono, Antonio
    Rask-Madsen, Christian
    Haas, Joel T.
    Aleman, Jose O.
    Suzuki, Ryo
    Scapa, Erez F.
    Agarwal, Chhavi
    Carey, Martin C.
    Stephanopoulos, Gregory
    Cohen, David E.
    King, George L.
    Ginsberg, Henry N.
    Kahn, C. Ronald
    [J]. CELL METABOLISM, 2008, 7 (02) : 125 - 134
  • [10] Intestine-specific expression of Apobec-1 rescues apolipoprotein B RNA editing and alters chylomicron production in Apobec1-/- mice
    Blanc, Valerie
    Xie, Yan
    Luo, Jianyang
    Kennedy, Susan
    Davidson, Nicholas O.
    [J]. JOURNAL OF LIPID RESEARCH, 2012, 53 (12) : 2643 - 2655